Cassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.